Canaccord Genuity Reiterates a 'Buy' on Amicus Therapeutics (FOLD); Encouraged on Upcoming Data
Tweet
Share
E-mailGet Alerts FOLD Hot Sheet
Price: $14.49 --0%
Rating Summary:
12 Buy, 9 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
12 Buy, 9 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Amicus Therapeutics (NASDAQ: FOLD) price target of $10.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on potential positive migalastat pivotal Fabry monoTx data Q3/12, chaperone/ERT comboTx for Fabry, Pompe. We think Q3 pivotal migalastat Fabry monoTx ‘011 trial data will be a strong positive catalyst. We think ‘011 has a high chance of success on Phase 2 precedent and trial enrichment. We also expect good top-line Phase 2 proof of concept AT2220/ERT Pompe combo data in Q2/12, similar to recent positive Fabry combo data."
"We are very encouraged by the enrollment rate of ’012, the migalastat EU pivotal trial. Given clinical site overlap with the ‘011 US trial, we think this reflects positively on safety and tolerability."
For an analyst ratings summary and ratings history on Amicus Therapeutics click here. For more ratings news on Amicus Therapeutics click here.
Shares of Amicus Therapeutics closed at $4.72 yesterday.
Analyst, Ritu Baral, said, "Reiterate rating and price target on potential positive migalastat pivotal Fabry monoTx data Q3/12, chaperone/ERT comboTx for Fabry, Pompe. We think Q3 pivotal migalastat Fabry monoTx ‘011 trial data will be a strong positive catalyst. We think ‘011 has a high chance of success on Phase 2 precedent and trial enrichment. We also expect good top-line Phase 2 proof of concept AT2220/ERT Pompe combo data in Q2/12, similar to recent positive Fabry combo data."
"We are very encouraged by the enrollment rate of ’012, the migalastat EU pivotal trial. Given clinical site overlap with the ‘011 US trial, we think this reflects positively on safety and tolerability."
For an analyst ratings summary and ratings history on Amicus Therapeutics click here. For more ratings news on Amicus Therapeutics click here.
Shares of Amicus Therapeutics closed at $4.72 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
- Nutanix (NTNX) PT Raised to $80 at Oppenheimer Into EPS
- Okta, Inc (OKTA) PT Raised to $170 at Cantor Fitzgerald Ahead of Q2 Results
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
